Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.38 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | CRHBP | P24387 | 1/20 | 0.35 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19746420 | 0.82 | SMN1; SMN2 (0.49) | SMN1; SMN2ALDH1A1LMNAHPGDMAPT | |
| SCHEMBL15217613 | 0.78 | SMN1; SMN2 (0.45) | SMN1; SMN2ALDH1A1LMNAHPGDMAPT | |
| SCHEMBL15217619 | 0.78 | SMN1; SMN2 (0.42) | SMN1; SMN2ALDH1A1LMNAHPGDMAPT | |
| SCHEMBL15217622 | 0.78 | SMN1; SMN2 (0.45) | SMN1; SMN2ALDH1A1LMNAHPGDMAPT | |
| SCHEMBL15217609 | 0.78 | SMN1; SMN2 (0.45) | SMN1; SMN2ALDH1A1LMNAHPGDMAPT | |
| SCHEMBL23914629 | 0.78 | SMN1; SMN2 (0.51) | SMN1; SMN2ALDH1A1LMNAHPGDMAPT | |
| SCHEMBL24661307 | 0.76 | SMN1; SMN2 (0.41) | SMN1; SMN2ALDH1A1LMNAHPGDMAPT | |
| SCHEMBL23915506 | 0.76 | SMN1; SMN2 (0.52) | SMN1; SMN2ALDH1A1LMNAHPGDMAPT | |
| SCHEMBL9378653 | 0.76 | SMN1; SMN2 (0.51) | SMN1; SMN2ALDH1A1LMNAHPGD | |
| SCHEMBL9377801 | 0.76 | SMN1; SMN2 (0.51) | SMN1; SMN2ALDH1A1LMNAHPGDPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11730737-B2 | Aldose reductase inhibitors and uses thereof | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2023-08-22 | — | — | US | disclosed |
| US-20170319584-A1 | ALDOSE REDUCTASE INHIBITORS AND USES THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2017-11-09 | — | — | US | disclosed |
| US-20170216292-A1 | ALDOSE REDUCTASE INHIBITORS AND USES THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2017-08-03 | — | — | US | disclosed |
| US-20170216291-A1 | ALDOSE REDUCTASE INHIBITORS AND USES THEREOF | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2017-08-03 | — | — | US | disclosed |
| US-9650383-B2 | Aldose reductase inhibitors and uses thereof | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2017-05-16 | — | — | US | disclosed |
| US-20150072989-A1 | ALDOSE REDUCTASE INHIBITORS AND USES THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-03-12 | — | — | US | disclosed |
| US-8916563-B2 | Aldose reductase inhibitors and uses thereof | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2014-12-23 | — | — | US | disclosed |
| US-20130225592-A1 | ALDOSE REDUCTASE INHIBITORS AND USES THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2013-08-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170216291-A1 | ALDOSE REDUCTASE INHIBITORS AND USES THEREOF | ALDOA, AKR1B1, AKR1C2 | SMN1; SMN2 2204/4885ALDH1A1 18/4885LMNA 1361/4885 |
| US-20170319584-A1 | ALDOSE REDUCTASE INHIBITORS AND USES THEREOF | ALDOA, AKR1B1, AKR1C2 | SMN1; SMN2 2204/4885ALDH1A1 18/4885LMNA 1361/4885 |
| US-20170216292-A1 | ALDOSE REDUCTASE INHIBITORS AND USES THEREOF | ALDOA, AKR1B1, AKR1C2 | SMN1; SMN2 2204/4885ALDH1A1 18/4885LMNA 1361/4885 |
| US-20150072989-A1 | ALDOSE REDUCTASE INHIBITORS AND USES THEREOF | ALDOA, AKR1B1, AKR1C2 | SMN1; SMN2 2204/4885ALDH1A1 18/4885LMNA 1361/4885 |
| US-20130225592-A1 | ALDOSE REDUCTASE INHIBITORS AND USES THEREOF | ALDOA, AKR1B1, AKR1C2 | SMN1; SMN2 2204/4885ALDH1A1 18/4885LMNA 1361/4885 |
| US-11730737-B2 | Aldose reductase inhibitors and uses thereof | ALDOA, AKR1B1, AKR1C2 | SMN1; SMN2 2204/4885ALDH1A1 18/4885LMNA 1361/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.